MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era.
Diagnostice escape
MDR outbreak strains
Multidrug resistance
Resistance evolution
Treatment escape
Treatment failure
Tuberculosis
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
25 11 2020
25 11 2020
Historique:
received:
18
05
2020
accepted:
27
10
2020
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
6
11
2021
Statut:
epublish
Résumé
Multidrug-resistant (MDR) Mycobacterium tuberculosis complex strains not detected by commercial molecular drug susceptibility testing (mDST) assays due to the RpoB I491F resistance mutation are threatening the control of MDR tuberculosis (MDR-TB) in Eswatini. We investigate the evolution and spread of MDR strains in Eswatini with a focus on bedaquiline (BDQ) and clofazimine (CFZ) resistance using whole-genome sequencing in two collections ((1) national drug resistance survey, 2009-2010; (2) MDR strains from the Nhlangano region, 2014-2017). MDR strains in collection 1 had a high cluster rate (95%, 117/123 MDR strains) with 55% grouped into the two largest clusters (gCL3, n = 28; gCL10, n = 40). All gCL10 isolates, which likely emerged around 1993 (95% highest posterior density 1987-1998), carried the mutation RpoB I491F that is missed by commercial mDST assays. In addition, 21 (53%) gCL10 isolates shared a Rv0678 M146T mutation that correlated with elevated minimum inhibitory concentrations (MICs) to BDQ and CFZ compared to wild type isolates. gCL10 isolates with the Rv0678 M146T mutation were also detected in collection 2. The high clustering rate suggests that transmission has been driving the MDR-TB epidemic in Eswatini for three decades. The presence of MDR strains in Eswatini that are not detected by commercial mDST assays and have elevated MICs to BDQ and CFZ potentially jeopardizes the successful implementation of new MDR-TB treatment guidelines. Measures to limit the spread of these outbreak isolates need to be implemented urgently.
Sections du résumé
BACKGROUND
Multidrug-resistant (MDR) Mycobacterium tuberculosis complex strains not detected by commercial molecular drug susceptibility testing (mDST) assays due to the RpoB I491F resistance mutation are threatening the control of MDR tuberculosis (MDR-TB) in Eswatini.
METHODS
We investigate the evolution and spread of MDR strains in Eswatini with a focus on bedaquiline (BDQ) and clofazimine (CFZ) resistance using whole-genome sequencing in two collections ((1) national drug resistance survey, 2009-2010; (2) MDR strains from the Nhlangano region, 2014-2017).
RESULTS
MDR strains in collection 1 had a high cluster rate (95%, 117/123 MDR strains) with 55% grouped into the two largest clusters (gCL3, n = 28; gCL10, n = 40). All gCL10 isolates, which likely emerged around 1993 (95% highest posterior density 1987-1998), carried the mutation RpoB I491F that is missed by commercial mDST assays. In addition, 21 (53%) gCL10 isolates shared a Rv0678 M146T mutation that correlated with elevated minimum inhibitory concentrations (MICs) to BDQ and CFZ compared to wild type isolates. gCL10 isolates with the Rv0678 M146T mutation were also detected in collection 2.
CONCLUSION
The high clustering rate suggests that transmission has been driving the MDR-TB epidemic in Eswatini for three decades. The presence of MDR strains in Eswatini that are not detected by commercial mDST assays and have elevated MICs to BDQ and CFZ potentially jeopardizes the successful implementation of new MDR-TB treatment guidelines. Measures to limit the spread of these outbreak isolates need to be implemented urgently.
Identifiants
pubmed: 33239092
doi: 10.1186/s13073-020-00793-8
pii: 10.1186/s13073-020-00793-8
pmc: PMC7687760
doi:
Substances chimiques
Antitubercular Agents
0
Bacterial Proteins
0
Diarylquinolines
0
bedaquiline
78846I289Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Références
EBioMedicine. 2018 Feb;28:136-142
pubmed: 29337135
Public Health Action. 2015 Jun 21;5(2):140-6
pubmed: 26400386
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28320727
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1564-1568
pubmed: 32053752
Eur Respir J. 2020 Sep 17;:
pubmed: 32943401
J Clin Microbiol. 2015 Jun;53(6):1806-11
pubmed: 25762769
Lancet. 2014 Apr 5;383(9924):1193-4
pubmed: 24439236
PLoS Med. 2013;10(2):e1001387
pubmed: 23424287
PLoS Pathog. 2018 Oct 18;14(10):e1007297
pubmed: 30335850
N Engl J Med. 2015 Mar 19;372(12):1181-2
pubmed: 25785984
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32060065
Am J Respir Crit Care Med. 2019 Aug 15;200(4):514-515
pubmed: 31026398
Genome Med. 2020 Mar 6;12(1):27
pubmed: 32143680
Lancet Infect Dis. 2018 Jun;18(6):675-683
pubmed: 29574065
PLoS One. 2017 Dec 27;12(12):e0189838
pubmed: 29281674
Eur Respir J. 2020 Aug 6;:
pubmed: 32764113
Antimicrob Agents Chemother. 2012 Dec;56(12):6080-7
pubmed: 23006760
J Antimicrob Chemother. 2017 Mar 1;72(3):684-690
pubmed: 28031270
Emerg Infect Dis. 2012 Jan;18(1):29-37
pubmed: 22260950
Public Health Action. 2017 Sep 21;7(3):240-242
pubmed: 29201660
N Engl J Med. 2019 May 30;380(22):2178-2180
pubmed: 31141643
Infect Genet Evol. 2012 Jun;12(4):748-54
pubmed: 22342955
Clin Infect Dis. 2019 Sep 13;69(7):1229-1231
pubmed: 30933266
Elife. 2018 Oct 30;7:
pubmed: 30373719
Clin Infect Dis. 2018 May 2;66(10):1625-1630
pubmed: 29126225
J Antimicrob Chemother. 2015 Sep;70(9):2427-39
pubmed: 26089441
J Clin Microbiol. 2019 Aug 26;57(9):
pubmed: 31315957
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32229496
Lancet Infect Dis. 2018 Dec;18(12):1350-1359
pubmed: 30342828
Emerg Infect Dis. 2019 Mar;25(3):564-568
pubmed: 30789124
J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043
pubmed: 32361756
Nucleic Acids Res. 2011 Jan;39(Database issue):D28-31
pubmed: 20972220
Lancet Microbe. 2020 Aug;1(4):e165-e174
pubmed: 32803174
Int J Infect Dis. 2019 Mar;80S:S32-S35
pubmed: 30818049
Clin Microbiol Infect. 2020 Nov;26(11):1453-1455
pubmed: 32768492